Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company's Special General Meeting of shareholders held on August 15, 2025The Company is initially planning to invest up to $10M representing approximately 50% of its current cash balance to be deployed in execution of an active digital asset management strategy which may include covered call options, staking, lending, and yield-generating protocolsGalmed is in the process of engaging Tectona Ltd. (TASE: TECT), a specialized crypto treasury management service provider, to advise and implement digital asset strategy by
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.Strategic collaboration with Proteas Health positions Galmed at the forefront of AI-driven biomarker-guided therapeutics.TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI
TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte
Canaccord Genuity reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $29.00 previously
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
EFFECT - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
424B3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)
SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)
SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)
TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte
TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments Recent Developments Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University;Formed a str
TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022. Recent Developments Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications.Implementing a cost reduction plan that includes reduction in headc